Acacia Pharma raises $23.
We have high expectations for APD403 and for the future success of the ongoing organization. .. Acacia Pharma raises $23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond Ventures participated in the round also. Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo A/S have joined the Plank of Acacia Pharma as Non-executive Directors. Acacia Pharma will use the proceeds to: complete Phase III development of APD421 for preventing post-operative nausea & vomiting ; complete Phase II advancement of APD403 for preventing chemotherapy induced nausea & vomiting ; and develop the commercial demonstration of APD515 for the treating xerostomia in advanced cancer individuals.Team. Related StoriesHIFU Prostate Providers announces groundbreaking partnerships to offer prostate cancers treatmentsResearchers perform first focused ultrasound treatments in the U.S. Aylor, dean of U.Va.’s College of Engineering and Applied Research.S. About the University of Virginia School of Engineering and Applied Technology Founded in 1836, the University of Virginia College of Engineering and Applied Research combines study and educational possibilities at the undergraduate and graduate amounts. Within the undergraduate applications, classes in engineering, ethics, mathematics, the sciences and the humanities are available to create a strong basis for professions in engineering and additional professions.